B7-33

B7-33 is a peptide that mimics the natural hormone relaxin-2, helping reduce scarring (fibrosis) and inflammation, while supporting heart and tissue health. B7-33 is a synthetic peptide derived from human relaxin-2, engineered to selectively activate the relaxin receptor (RXFP1). This peptide retains the anti-fibrotic, anti-inflammatory, and cardioprotective effects of relaxin-2 while minimizing vasodilatory side effects. It works by improving blood flow, breaking down excess collagen, and promoting tissue healing, making it a potential treatment for conditions like heart or lung fibrosis and chronic inflammation. B7-33 demonstrates significant potential in treating fibrotic diseases, improving cardiac function, and promoting tissue repair and regeneration.

- Reduce fibrosis (scarring) and inflammation, especially in conditions affecting the heart, lungs, or other tissues

- Seek cardiovascular or tissue repair support, particularly for improving blood flow and reducing excess collagen buildup

How this peptide works in the body

RXFP1 Activation:

• B7-33 selectively binds to the relaxin family peptide receptor 1 (RXFP1), activating the cyclic AMP-protein kinase A (cAMP-PKA) signaling pathway. This activation reduces fibrosis, improves endothelial function, and enhances vascular relaxation, leading to better blood flow and reduced tissue stiffness in the heart, lungs, and other organs.

AT2R Activation:

• By interacting with the angiotensin II receptor type 2 (AT2R), B7-33 counteracts the effects of angiotensin II, which helps lower blood pressure and inflammation. This pathway also reduces ACE2 receptor transcription, potentially limiting viral entry in conditions like COVID-19-associated lung injury.

Anti-Fibrotic Effects:

• B7-33 inhibits collagen deposition by activating matrix metalloproteinases (MMPs), enzymes responsible for breaking down excess extracellular matrix proteins. This effect prevents scarring and fibrosis progression in tissues like the heart, liver, and lungs, making it a promising treatment for fibrotic diseases.

Anti-Inflammatory Action:

• B7-33 reduces the expression of pro-inflammatory cytokines such as TNF-α and IL-6 while upregulating elastin synthesis and vascular remodeling proteins. This leads to lower systemic inflammation and improved tissue elasticity, benefiting conditions like pulmonary hypertension and chronic inflammation.

Cardiovascular Protection:

• By enhancing myocardial relaxation and reducing systemic vascular resistance, B7-33 improves cardiac output and protects against heart failure. It also supports pulmonary circulation by reducing pulmonary artery pressure, making it beneficial for vascular diseases and hypertension.

Tissue Regeneration:

• B7-33 stimulates angiogenesis by upregulating vascular endothelial growth factor (VEGF), improving endothelial cell function, and accelerating wound healing and organ repair. This promotes better oxygen delivery and faster recovery from tissue damage.